2015 Press Releases

2015 | 2014 | 2013
Keyword Search
 
DateTitle 
07/29/15Depomed Reports Record Sales and Cash Flow in Second Quarter 2015 and Raises Full Year 2015 GuidancePrinter Friendly Version
07/29/15Depomed's Board of Directors Unanimously Rejects Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plcPrinter Friendly Version
07/29/15Depomed to Report Second Quarter Fiscal Year 2015 Financial Results on Wednesday, July 29, 2015Printer Friendly Version
07/21/15Depomed Confirms Receipt of Purported Revised, Highly Conditional, Unsolicited Proposal from Horizon Pharma plcPrinter Friendly Version
07/08/15Depomed Announces Decision in Inter Partes Review Proceeding against Purdue Pharma Confirming Patentability of All Challenged ClaimsPrinter Friendly Version
07/07/15Depomed Confirms Receipt of Unsolicited Proposal from Horizon Pharma plcPrinter Friendly Version
06/17/15Depomed Announces Change To Presentation Time At JMP Life Sciences ConferencePrinter Friendly Version
06/03/15Depomed Announces Zipsor® ANDA Litigation Settlement Providing for Exclusivity to March 2022Printer Friendly Version
05/26/15Depomed To Present At Healthcare Conferences In JunePrinter Friendly Version
05/13/15Depomed To Present At Healthcare Conferences In MayPrinter Friendly Version
05/11/15Depomed Reports First Quarter 2015 Financial ResultsPrinter Friendly Version
04/30/15Depomed to Report First Quarter Fiscal Year 2015 Financial Results on Monday, May 11, 2015Printer Friendly Version
04/13/15Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing AppealPrinter Friendly Version
04/02/15Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billionPrinter Friendly Version
03/17/15Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen PharmaceuticalsPrinter Friendly Version
03/12/15Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® AcquisitionPrinter Friendly Version
03/03/15Depomed To Present At 27th Annual Roth ConferencePrinter Friendly Version
02/23/15Depomed Reports Fourth Quarter and Full Year 2014 Financial ResultsPrinter Friendly Version
02/12/15Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015Printer Friendly Version
02/09/15New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of EvidencePrinter Friendly Version
02/04/15Depomed To Present At Healthcare Conferences In FebruaryPrinter Friendly Version
01/15/15Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billionPrinter Friendly Version

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$31.50
Change (%)
 + 0.97 (3.18%)
Volume
2,021,475
Market Cap
$1,888,834,500

Data as of 07/31/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.